MOLN revenueFY2025CHF 0
- FY YoY
- -100.0%
MOLN revenue was CHF 0 for fiscal 2025 (ended Dec 31, 2025), down 100.0% from fiscal 2024.
Molecular Partners AG (MOLN) financials
For fiscal 2025 (ended Dec 31, 2025), Molecular Partners AG reported CHF 0 of revenue and -CHF 61.65M of net income. Figures are in CHF, the currency of its SEC filings.
- Revenue, FY2025
- CHF 0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -CHF 61.65M
- Free cash flow, FY2025
- -CHF 51.97M
- EPS, diluted, FY2025
- -CHF 1.65
- Cash
- CHF 82.65M
FY2019FY2025
FY2019FY2025
FY2019FY2025
MOLN revenue and earnings growth
MOLN net incomeFY2025-CHF 61.65M
MOLN net income was -CHF 61.65M for fiscal 2025 (ended Dec 31, 2025), compared with -CHF 54.04M in fiscal 2024.
MOLN EPSFY2025-CHF 1.65
MOLN diluted EPS was -CHF 1.65 for fiscal 2025 (ended Dec 31, 2025), compared with -CHF 1.59 in fiscal 2024.
MOLN free cash flowFY2025-CHF 51.97M
MOLN free cash flow was -CHF 51.97M for fiscal 2025 (ended Dec 31, 2025), compared with -CHF 59.95M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | CHF 0 | CHF 4.97M | CHF 7.04M | CHF 189.60M | CHF 9.75M | CHF 9.34M | CHF 20.38M |
| Research and development | CHF 40.19M | CHF 48.60M | CHF 48.78M | CHF 50.75M | CHF 55.72M | CHF 56.08M | CHF 43.50M |
| Selling, general and admin | CHF 15.24M | CHF 17.58M | CHF 19.36M | CHF 22.24M | CHF 17.45M | CHF 11.60M | CHF 13.54M |
| Operating income | -CHF 58.12M | -CHF 61.22M | -CHF 61.11M | CHF 116.61M | -CHF 63.42M | -CHF 58.33M | -CHF 36.66M |
| Interest expense | CHF 5.05M | CHF 38.0K | CHF 5.16M | CHF 619.0K | CHF 556.0K | CHF 4.82M | CHF 1.21M |
| Pre-tax income | -CHF 61.65M | -CHF 54.04M | -CHF 61.98M | CHF 117.85M | -CHF 63.78M | -CHF 62.77M | -CHF 36.27M |
| Income tax | CHF 2.0K | CHF 2.0K | CHF 0 | CHF 0 | CHF 2.0K | -CHF 11.0K | CHF 17.0K |
| Net income | -CHF 61.65M | -CHF 54.04M | -CHF 61.98M | CHF 117.85M | -CHF 63.78M | -CHF 62.76M | -CHF 36.29M |
| EPS, basic | -CHF 1.65 | -CHF 1.59 | -CHF 1.89 | CHF 3.63 | -CHF 2.06 | -CHF 2.51 | -CHF 1.69 |
| EPS, diluted | -CHF 1.65 | -CHF 1.59 | -CHF 1.89 | CHF 3.54 | -CHF 2.06 | -CHF 2.51 | -CHF 1.69 |
| Diluted shares | 37.3M | 34.0M | 32.8M | 33.3M | 31.0M | 25.0M | 21.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | CHF 82.65M | CHF 63.87M | CHF 67.31M | CHF 87.95M | CHF 71.81M | CHF 133.72M | CHF 75.71M |
| Receivables | CHF 1.83M | CHF 2.32M | CHF 1.95M | CHF 1.02M | CHF 25.65M | CHF 2.84M | - |
| Current assets | CHF 96.88M | CHF 154.28M | CHF 192.46M | CHF 254.75M | CHF 164.19M | CHF 177.81M | - |
| Total assets | CHF 102.11M | CHF 158.53M | CHF 198.35M | CHF 262.26M | CHF 172.67M | CHF 187.55M | - |
| Current liabilities | CHF 11.03M | CHF 10.79M | CHF 14.42M | CHF 17.25M | CHF 46.87M | CHF 57.67M | - |
| Total liabilities | CHF 21.77M | CHF 16.89M | CHF 21.92M | CHF 27.09M | CHF 65.38M | CHF 80.33M | - |
| Shareholders' equity | CHF 80.33M | CHF 141.64M | CHF 176.43M | CHF 235.17M | CHF 107.29M | CHF 107.22M | CHF 54.14M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -CHF 51.26M | -CHF 59.25M | -CHF 59.01M | CHF 118.57M | -CHF 90.95M | -CHF 28.98M | -CHF 1.19M |
| Capital expenditures | CHF 714.0K | CHF 705.0K | CHF 575.0K | CHF 1.18M | CHF 933.0K | CHF 1.45M | CHF 1.03M |
| Free cash flow | -CHF 51.97M | -CHF 59.95M | -CHF 59.58M | CHF 117.39M | -CHF 91.89M | -CHF 30.43M | -CHF 2.22M |
| Investing cash flow | CHF 72.55M | CHF 40.49M | CHF 44.64M | -CHF 101.12M | -CHF 22.24M | -CHF 21.75M | -CHF 19.84M |
| Financing cash flow | -CHF 1.15M | CHF 14.43M | -CHF 1.17M | -CHF 1.57M | CHF 50.58M | CHF 113.20M | -CHF 227.0K |
| Share repurchases | - | CHF 0 | CHF 0 | CHF 631.0K | CHF 0 | CHF 0 | - |
| Stock-based compensation | CHF 4.42M | CHF 4.11M | CHF 5.21M | CHF 5.09M | CHF 4.08M | CHF 2.93M | CHF 2.44M |
| Depreciation and amortization | CHF 2.14M | CHF 2.37M | CHF 2.42M | CHF 2.39M | CHF 2.56M | CHF 2.89M | CHF 2.47M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | -29.4% | -96.3% | 1843.8% | 4.4% | -54.2% | - |
| Operating margin | - | -1231.7% | -868.3% | 61.5% | -650.2% | -624.2% | -179.9% |
| Net margin | - | -1087.4% | -880.7% | 62.2% | -653.9% | -671.7% | -178.0% |
| Free cash flow margin | - | -1206.3% | -846.5% | 61.9% | -942.0% | -325.7% | -10.9% |
| Return on equity | -76.7% | -38.2% | -35.1% | 50.1% | -59.5% | -58.5% | -67.0% |
| Return on assets | -60.4% | -34.1% | -31.2% | 44.9% | -36.9% | -33.5% | - |
| Current ratio | 8.79 | 14.31 | 13.35 | 14.77 | 3.50 | 3.08 | - |
Source: XBRL data Molecular Partners AG files with the SEC, latest filing dated Mar 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
MOLN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MOLN | CHF 0 | -100.0% | -CHF 61.65M | - | $115.9M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
MOLN FAQ
8 questionsWhat is MOLN revenue?
Molecular Partners AG (MOLN) reported CHF 0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is MOLN profitable?
No. Molecular Partners AG reported a net loss of CHF 61.65M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does MOLN have?
Molecular Partners AG reported CHF 82.65M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is MOLN revenue growing?
Molecular Partners AG's revenue changed -100.0% in fiscal 2025, to CHF 0.What is MOLN free cash flow?
Molecular Partners AG generated -CHF 51.97M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -CHF 51.26M less capital expenditures.What is MOLN earnings per share?
Diluted earnings per share were -CHF 1.65 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did MOLN last report financial results?
The latest statements here come from Molecular Partners AG's 20-F filed on Mar 12, 2026, covering the period ended Dec 31, 2025.Where does this MOLN financial data come from?
Quantisnow builds these statements from the structured XBRL data Molecular Partners AG files with the SEC. It is provided for information only and is not investment advice.